PURPOSE: The aim of this study is to elucidate the impact of preoperative and postoperative pulmonary hypertension (PH) on long-term clinical outcomes after mitral valve repair for degenerative mitral regurgitation. METHODS: A total of 654 patients who underwent mitral valve repair for degenerative mitral regurgitation between 1991 and 2010 were retrospectively reviewed. Patients were divided into PH(+) group (137 patients) and PH(-) group (517 patients). Follow-up was complete in 99.0%. The median follow-up duration was 7.5 years. RESULTS: Patients in PH(+) group were older, more symptomatic and had higher tricuspid regurgitation grade. Thirty-day mortality was not different between 2 groups (p = 0.975). Long-term survival rate was lower in PH(+) group; 10-year survival rate after the operation was 85.2% ± 4.0% in PH(+) group and 89.7% ± 1.8% in PH(-) group (Log-rank, p = 0.019). The incidence of late cardiac events were not different between groups, however, the recurrence of PH was more frequent in PH(+) group. The recurrence of PH had an adverse impact on survival rate, late cardiac events and symptoms. Univariate analysis showed age and preoperative tricuspid regurgitation grade were the predictors of PH recurrence. CONCLUSION: Early surgical indication should be advocated for degenerative mitral regurgitation before the progression of pulmonary hypertension and tricuspid regurgitation.
PURPOSE: The aim of this study is to elucidate the impact of preoperative and postoperative pulmonary hypertension (PH) on long-term clinical outcomes after mitral valve repair for degenerative mitral regurgitation. METHODS: A total of 654 patients who underwent mitral valve repair for degenerative mitral regurgitation between 1991 and 2010 were retrospectively reviewed. Patients were divided into PH(+) group (137 patients) and PH(-) group (517 patients). Follow-up was complete in 99.0%. The median follow-up duration was 7.5 years. RESULTS:Patients in PH(+) group were older, more symptomatic and had higher tricuspid regurgitation grade. Thirty-day mortality was not different between 2 groups (p = 0.975). Long-term survival rate was lower in PH(+) group; 10-year survival rate after the operation was 85.2% ± 4.0% in PH(+) group and 89.7% ± 1.8% in PH(-) group (Log-rank, p = 0.019). The incidence of late cardiac events were not different between groups, however, the recurrence of PH was more frequent in PH(+) group. The recurrence of PH had an adverse impact on survival rate, late cardiac events and symptoms. Univariate analysis showed age and preoperative tricuspid regurgitation grade were the predictors of PH recurrence. CONCLUSION: Early surgical indication should be advocated for degenerative mitral regurgitation before the progression of pulmonary hypertension and tricuspid regurgitation.
Authors: F Roques; S A Nashef; P Michel; E Gauducheau; C de Vincentiis; E Baudet; J Cortina; M David; A Faichney; F Gabrielle; E Gams; A Harjula; M T Jones; P P Pintor; R Salamon; L Thulin Journal: Eur J Cardiothorac Surg Date: 1999-06 Impact factor: 4.191
Authors: M H Crawford; J Souchek; C A Oprian; D C Miller; S Rahimtoola; J C Giacomini; G Sethi; K E Hammermeister Journal: Circulation Date: 1990-04 Impact factor: 29.690
Authors: Andrew B Goldstone; Joanna Chikwe; Sean P Pinney; Anelechi C Anyanwu; Samuel A Funt; Antonio Polanco; David H Adams Journal: Am J Cardiol Date: 2011-03-01 Impact factor: 2.778
Authors: Andrea Barbieri; Francesca Bursi; Francesco Grigioni; Christophe Tribouilloy; Jean Francois Avierinos; Hector I Michelena; Dan Rusinaru; Catherine Szymansky; Antonio Russo; Rakesh Suri; Maria Letizia Bacchi Reggiani; Angelo Branzi; Maria Grazia Modena; Maurice Enriquez-Sarano Journal: Eur Heart J Date: 2010-09-08 Impact factor: 29.983
Authors: Robert O Bonow; Blase A Carabello; Kanu Chatterjee; Antonio C de Leon; David P Faxon; Michael D Freed; William H Gaasch; Bruce W Lytle; Rick A Nishimura; Patrick T O'Gara; Robert A O'Rourke; Catherine M Otto; Pravin M Shah; Jack S Shanewise Journal: Circulation Date: 2008-09-26 Impact factor: 29.690
Authors: Javier Bermejo; Raquel Yotti; Rocío García-Orta; Pedro L Sánchez-Fernández; Mario Castaño; Javier Segovia-Cubero; Pilar Escribano-Subías; José Alberto San Román; Xavier Borrás; Angel Alonso-Gómez; Javier Botas; María G Crespo-Leiro; Sonia Velasco; Antoni Bayés-Genís; Amador López; Roberto Muñoz-Aguilera; Eduardo de Teresa; José R González-Juanatey; Arturo Evangelista; Teresa Mombiela; Ana González-Mansilla; Jaime Elízaga; Javier Martín-Moreiras; José M González-Santos; Eduardo Moreno-Escobar; Francisco Fernández-Avilés Journal: Eur Heart J Date: 2018-04-14 Impact factor: 29.983
Authors: Javier Bermejo; Ana González-Mansilla; Teresa Mombiela; Ana I Fernández; Pablo Martínez-Legazpi; Raquel Yotti; Rocío García-Orta; Pedro L Sánchez-Fernández; Mario Castaño; Javier Segovia-Cubero; Pilar Escribano-Subias; J Alberto San Román; Xavier Borrás; Angel Alonso-Gómez; Javier Botas; María G Crespo-Leiro; Sonia Velasco; Antoni Bayés-Genís; Amador López; Roberto Muñoz-Aguilera; Manuel Jiménez-Navarro; José R González-Juanatey; Arturo Evangelista; Jaime Elízaga; Javier Martín-Moreiras; José M González-Santos; Eduardo Moreno-Escobar; Francisco Fernández-Avilés Journal: J Am Heart Assoc Date: 2021-01-05 Impact factor: 5.501
Authors: C Lavalle; M Straito; E Chourda; S Poggi; G Frati; W Saade; A G M Marullo; M V Mariani; M Magnocavallo; F Miraldi Journal: Cardiol Res Pract Date: 2021-08-02 Impact factor: 1.866
Authors: M Hünlich; E Lubos; B E Beuthner; M Puls; A Bleckmann; T Beißbarth; T Tichelbäcker; V Rudolph; S Baldus; U Schäfer; H Treede; R S Von Bardeleben; S Blankenberg; W Schillinger Journal: Biomed Res Int Date: 2018-03-14 Impact factor: 3.411